• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Pharmaxis - Articles and news items

Successful Phase 1 results for cardiometabolic disease drug PXS-4728A

Industry news / 22 September 2015 / Victoria White

PXS-4728A is a highly selective inhibitor of an enzyme and adhesion protein which reduces inflammation and oxidative stress…


Boehringer Ingelheim acquires Pharmaxis’ investigational drug PXS4728A

Industry news / 18 May 2015 / Victoria White

Boehringer Ingelheim has acquired Pharmaxis’ investigational drug PXS4728A, to develop it for the treatment of NASH and to prevent its consequences…